Prognostic factors in patients who received autologous bone marrow transplantation for non-Hodgkin's lymphoma. Report of 104 patients from the Spanish Cooperative Group GEL/TAMO.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Bone Marrow Transplantation

• Publication date

  1994-08-01

• Fields of study

  Medicine

• Identifiers
  PMID 7994243
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Autologous bone marrow transplantation for patients with aggressive non-Hodgkin's lymphoma.

  1992cited by this paper
• Autologous bone marrow transplantation in 22 adult patients with lymphoblastic lymphoma responsive to conventional dose chemotherapy.

  1992cited by this paper
• High-dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: a pilot study.

  1992cited by this paper
• Role of high-dose chemotherapy and autologous bone marrow transplantation in the treatment of lymphoma.

  1991cited by this paper
• P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil.

  1991cited by this paper
• Autologous bone marrow transplantation for non‐Hodgkin's lymphoma

  1991cited by this paper
• Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B.

  1991cited by this paper
• Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs.

  1991cited by this paper
• Autotransplantation in lymphoma: better therapy or healthier patients?

  1991cited by this paper
• Autologous bone marrow transplantation as consolidation therapy for non-Hodgkin's lymphoma patients with poor prognostic features.

  1991cited by this paper
• Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.

  1991cited by this paper
• The role of bone marrow transplantation in the non-Hodgkin's lymphomas.

  1990cited by this paper
• Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle.

  1990cited by this paper
• [The treatment of non-Hodgkin's lymphomas].

  1990cited by this paper
• The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous marrow transplantation.

  1990cited by this paper
• Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse.

  1990cited by this paper
• Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study.

  1990cited by this paper
• Treatment options for recurrent lymphomas.

  1990cited by this paper
• Bone marrow transplantation in the treatment of patients with lymphoma.

  1989cited by this paper
• Prognosis of aggressive lymphomas: a study of five prognostic models with patients included in the LNH-84 regimen.

  1989cited by this paper
• Autologous bone marrow transplantation for patients with poor-prognosis lymphoma.

  1988cited by this paper
• Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP).

  1988cited by this paper
• Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis.

  1987cited by this paper
• High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.

  1987cited by this paper
• Results of MIME salvage regimen for recurrent or refractory lymphoma.

  1987cited by this paper
• Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma.

  1986cited by this paper
• High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease.

  1986cited by this paper
• Predictive model for prognosis in advanced diffuse histiocytic lymphoma.

  1986cited by this paper
• Clinical studies of ABMT in non-Hodgkin's lymphoma.

  1986cited by this paper
• Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD.

  1986cited by this paper
• MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma.

  1985cited by this paper
• An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults.

  1984cited by this paper
• Nonparametric confidence limits for survival probabilities and median survival time.

  1982cited by this paper
• Dose: a critical factor in cancer chemotherapy.

  1980cited by this paper
• Cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (COMLA) combination sequential chemotherapy for advanced diffuse histiocytic lymphoma.

  1980cited by this paper
• Non‐Hodgkin's lymphoma in children. A progress report on the original patients treated with the LSA2‐L2 protocol

  1979cited by this paper
• Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma

  1976cited by this paper
• Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone.

  1972cited by this paper

• ESHAP versus GEMOX in Management of Relapsed or Refractory Lymphoma: A Prospective Randomized Study

  2018cites this paper
• Prognostic factors in patients with relapsed or refractory diffuse large B-cell lymphoma who underwent autologous stem-cell transplantation

  2016cites this paper
• Prognostic factors in patients with aggressive non-Hodgkin’s lymphoma without complete response to first-line therapy

  2006cites this paper
• Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma.

  2006cites this paper
• Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation.

  2005cites this paper
• Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study

  2004cites this paper
• High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group.

  2003cites this paper
• ‘Relative’ chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma

  2002cites this paper
• Cytoreduction and Stem Cell Mobilization with a Regimen of Paclitaxel, Etoposide and Cyclophosphamide Followed by Autologous Transplantation Using a Preparative Regimen of Busulfan, Etoposide and Cyclophosphamide for Patients with Advanced Lymphoma

  2001cites this paper
• Autotransplants for histologically transformed follicular non‐Hodgkin's lymphoma

  2001cites this paper
• Prognostic features and outcome in patients with diffuse large B‐cell lymphoma who do not achieve a complete response to first‐line regimens

  2001cites this paper
• [Therapy intensification with autologous transplantation in non-Hodgkin's lymphomas].

  2001cites this paper
• Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens

  2001cites this paper
• The management of adult aggressive non-Hodgkin's lymphomas.

  2000cites this paper
• The VIM3-AraC regimen followed by autologous stem cell transplantation in refractory or relapsing aggressive non-Hodgkin's lymphoma. A prospective study of 71 consecutive cases

  1999cites this paper
• Autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.

  1999cites this paper
• [Intensive therapy in non-Hodgkins lymphoma. Indications and modalities].

  1998cites this paper
• Durability of remission after ABMT for NHL: the importance of the 2-year evaluation point

  1997cites this paper
• The clinical value of lactate dehydrogenase in serum: a quantitative review.

  1997cites this paper
• Bone marrow transplantation for non-Hodgkin's lymphoma: a review.

  1997cites this paper
• Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation.

  1997cites this paper
• BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors

  1997cites this paper
• Prognostic factors for survival of non-Hodgkin's lymphoma patients treated with high-dose chemotherapy and autologous bone marrow transplantation.

  1996cites this paper
• Clinical research at the postgraduate school of haematology 'Farreras-Valentí'.

  1996cites this paper
• The Role of Intensive Therapy and Autologous Blood and Marrow Transplantation for Chemotherapy‐Sensitive Relapsed and Primary Refractory Non‐Hodgkin’s Lymphoma: Identification of Major Prognostic Groups

  1996cites this paper
• [Research on prognostic factors in large-cell lymphomas].

  1995cites this paper